In This Section

Program

Please note that this meeting will take place as an in-person event in Austin and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the Registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program is subject to change.

[R] – Remote Presentation
*– Short talk selected from proffered abstracts

thursday, november 17, 2022

Preneoplasia: Definitions, PreCancer Atlas and Resources
NCI-Sponsored Grant Writing Course
Welcome and Introduction
Opening Keynote Address
A Vision for The Future of Cancer Prevention: Three Perspectives

friday, november 18, 2022

Breakfast Session I: Multicancer Early Detection Tests; New Data and Perspectives from Biotech Part I
Plenary Session 1: What Will Cancer Prevention and Early Detection Look like in 2041? 
Plenary Session 2:  Defining a Molecular Basis for Cancer Prevention and Early Detection
Panel Discussion: How Can We Merge Novel Technologies with Knowledge of Cancer Mechanisms to Improve Early Detection of Cancer? 
Plenary Session 3: Preneoplastic Conditions as a Model for Early Detection 
Plenary Session 4:  Innovative Approaches for Implementation – Community, Regulatory, and Operational 
Spotlight on Proffered Papers I 

Saturday, november 19, 2022

Breakfast Session II: New Data and Perspectives from Biotech Part II
Keynote Address
Plenary Session 5: Prevention and Interception 
Spotlight on Proffered Papers II 
Plenary Session 6:  Technological Advances and Their Application in Early Detection  

thursday, november 17, 2022

preneoplasia: definitions, precancer atlas and resources
not eligible for cme credit
session chair: sudhir srivastava, national cancer institute, bethesda, maryland
3-5 p.m.

Panelists:

Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, Texas

Eduardo Vilar-Sanchez, The University of Texas MD Anderson Cancer Center, Houston, Texas

Mary L. Disis, University of Washington, Seattle, Washington

Veronica M. Rotemberg, Memorial Sloan Kettering Cancer Center

Adewole S. Adamson, The University of Texas at Austin Dell Medical School, Austin, Texas

NCI-Sponsored grant writing course
not eligible for cme credit
session chair: to be announced
3-5 p.m.
Welcome and introduction 
6-6:10 p.m.

Welcome from conference chair and cochairs

CME Icon
opening keynote address
6:10-7 P.m.

Introduction of keynote speaker
Timothy R. Rebbeck, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

Title to be announced
Douglas R. Lowy, National Cancer Institute, Bethesda, Maryland

CME Icon
a vision for the future of cancer prevention: three perspectives 
7-8 p.m. 

Title to be announced 
Adriana Albini, University Milano-Bicocca, Milan, Italy [R]

Title to be announced 
Philip E. Castle, National Cancer Institute, Bethesda, Maryland

Title to be announced
David Crosby, Cancer Research UK, London, England, United Kingdom

Panel Discussion

Opening Reception  
8-9:30 p.m.

friday, november 18, 2022

Continental Breakfast 
7-8 a.m. 
breakfast session I: multicancer early detection tests; new data and perspectives from biotech part I
Not eligible for cme credit
session chair: christina clarke dur, GRAil, inc., menlo park, california
7-8 a.m.
break
8-8:30 A.m.
CME Icon
Plenary Session 1: What Will Cancer Prevention and Early Detection Look like in 2041? 
SESSION CHAIR: TIMOTHY R. REBBECK, DANA-FARBER CANCER INSTITUTE, HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH, BOSTON, MASSACHUSETTS 
8:30-10:00 a.m.   

Optimizing the public’s health through prevention and early detection (precision and otherwise) 
Timothy R. Rebbeck, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

Aspirin and cancer: What’s next?  
Andrew T. Chan, Massachusetts General Hospital, Boston, Massachusetts

Molecular imaging, radiomics and next generation sequencing: A tribute to Sam Gambhir’s vision
Katherine W. Ferrara, Stanford University, Stanford, California

Break 
10-10:30 a.m.  
CME Icon
plenary session 2: defining a molecular basis for cancer prevention and early detection
session chair: luis a. diaz, jr., memorial sloan kettering cancer center, new york, new york
10:30 a.m.-12 p.m.

Title to be announced
Nickolas Papadopoulos, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Title to be announced
Daniel D. De Carvalho, University Health Network Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Title to be announced
Victor E. Velculescu, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
   

Boxed Lunch 
12-1 p.m. 
CME Icon
Panel Discussion: How Can We Merge Novel Technologies with Knowledge of Cancer Mechanisms to Improve Early Detection of Cancer? 
MODERATOR: to be announced
12:15-1:15 p.m. 

Panelists:  

Joshua LaBaer, The Biodesign Institute at Arizona State University, Tempe, Arizona 

Sudhir Srivastava, National Cancer Institute, Bethesda, Maryland 

Victor E. Velculescu, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Break 
1:15-1:45 p.m. 
CME Icon
Plenary Session 3: Preneoplastic Conditions as a Model for Early Detection 
SESSION CHAIR: PHILIP w. KANTOFF, Convergent therapeutics, inc., cambridge, massachusetts
1:45-3:45 p.m. 

Title to be announced
Kelly L. Bolton, Washington University in St. Louis, St. Louis, Missouri

Title to be announced
Avrum E. Spira, Johnson & Johnson Innovation Center, Boston University, Boston, Massachusetts 

Title to be announced  
Veronica M. Rotemberg, Memorial Sloan Kettering Cancer Center, New York, New York

Break 
3:45-4:15 p.m. 
CME Icon
Plenary Session 4:  Innovative Approaches for Implementation – Community, Regulatory, and Operational  
SESSION CHAIR: ERNEST T. HAWK, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TEXAS
4:15-6:15 p.m. 

Title to be announced
Nora Pashayan, University College London, London, England, United Kingdom

Title to be announced 
Eduardo Vilar-Sanchez, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Title to be announced  
Ruth Rechis, The University of Texas MD Anderson Cancer Center, Houston, Texas  

Title to be announced  
Derek M. Griffith, Georgetown University, Washington, D.C.

Break 
6:15-6:30 p.m. 
CME Icon
Spotlight on Proffered Papers I 
SESSION CHAIR: PHILIP E. CASTLE, NATIONAL CANCER INSTITUTE, BETHESDA, MARYLAND
6:30-7:30 p.m. 
Poster Session / Reception 
7:30-9:30 p.m. 

Saturday, november 19, 2022 

Continental Breakfast   
7-8 a.m. 
Breakfast session II: new data and perspectives from biotech part II
not eligible for cme credit
session chair: christina clarke dur, grail, inc., menlo park, california
7-8 a.m.
break
8-8:30 a.m.
CME Icon
Keynote Address 
8:30-9:30 a.m. 

Introduction of keynote speaker 
Philip W. Kantoff, Convergent Therapeutics, Inc., Cambridge, Massachusetts

Title to be announced 
Minetta C. Liu, Mayo Clinic College of Medicine and Science, Rochester, Minnesota  

CME Icon
Plenary Session 5: Prevention and Interception 
SESSION CHAIR: LUIS A. DIAZ, JR., MEMORIAL SLOAN KETTERING CANCER CENTER, NEW YORK, NEW YORK 
9:30-11 a.m.  

Title to be announced 
Mary L. Disis, University of Washington, Seattle, Washington

Targeting mTOR for the prevention of triple-negative breast cancer
Powel H. Brown, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
Ruth D. Etzioni, Fred Hutchinson Cancer Research Center, Seattle, Washington

Boxed Lunch 
11 a.m.-12 p.m. 
CME Icon
Spotlight on Proffered Papers II 
session chair: PHILIP w. KANTOFF, Convergent therapeutics, inc., cambridge, massachusetts
11:15 a.m.-12:15 p.m. 

Break 
12:15-12:30 p.m. 
CME Icon
Plenary Session 6:  Technological Advances and Their Application in Early Detection  
This session is dedicated to the Work and Life of Sanjiv Sam Gambhir, MD, PhD 
SESSION CHAIR:  SANGEETA n. BHATIA, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MASSACHUSETTS 
12:30-2 p.m. 

Title to be announced
Sangeeta N. Bhatia, Massachusetts Institute of Technology, Cambridge, Massachusetts

Multiplexed analyses of extracellular vesicles for early cancer detection
Hakho Lee, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Title to be announced 
Samir M. Hanash, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Closing Remarks and departure
2-2:15 p.m. 

Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York

Times may change slightly as the program develops with the inclusion of short talks from proffered abstracts.